"FDA Clears Study Of Bacteriophages In IBD Treatment"- Alex Young
Biotech company, Intralytix, has obtained FDA clearance to begin a phase 1/2a study of bacteriophages specifically designed to treat inflammatory bowel disease. Principal investigator, Jean-Frédéric Colombel, MD, professor of medicine and gastroenterology at the Icahn School of Medicine at Mount Sinai and director of the Susan and Leonard IBD Clinical Center at Mount Sinai, said they will take a closer look at bacteriophages that specifically target adherent-invasive Escherichia coli (AIEC), a strain of bacteria that is regularly found in the mucosa of patients with Crohn's disease. "Several therapeutic strategies targeting AIEC colonization have been proposed to slow or even halt the natural course of CD," Dr. Colombel said. "Manipulation of the patient's microbiota through antibiotic treatment, fecal transplantation, nutritional interventions or the administration of pre/probiotics could be used either alone or in combination with immunotherapy, to induce the remission of active disease or as a postoperative treatment to prevent relapse. However, the results obtained to date have been inconsistent."
- Jean-Frédéric Colombel, MD, Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Director, Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai